|
Report No. : |
301738 |
|
Report Date : |
13.01.2015 |
IDENTIFICATION DETAILS
|
Name : |
SARL BIOCARE |
|
|
|
|
Registered Office : |
RN 44 Sidi Kassi Ben Mhidi El Tarf 36242 |
|
|
|
|
Country : |
Algeria |
|
|
|
|
Date of Incorporation : |
01.01.1998 |
|
|
|
|
Com. Reg. No.: |
98B0362106 |
|
|
|
|
Legal Form : |
Societe Anonyme Responsabilitee Limitee |
|
|
|
|
Line of Business : |
Subject
operate manufacture and supply of pharmaceuticals |
|
|
|
|
No. of Employees : |
457 |
RATING & COMMENTS
|
MIRA’s Rating : |
Ba |
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
41-55 |
Ba |
Overall operation is considered normal. Capable to meet normal commitments. |
Satisfactory |
|
Maximum Credit Limit : |
USD
300,000 |
|
Status : |
Satisfactory |
|
Payment Behaviour : |
No complaints |
|
Litigation : |
Clear |
NOTES :
Any query related to this report can be made
on e-mail : infodept@mirainform.com
while quoting report number, name and date.
ECGC Country Risk Classification List – September 30, 2014
|
Country Name |
Previous Rating (30.06.2014) |
Current Rating (30.09.2014) |
|
Algeria |
B2 |
B2 |
|
Risk Category |
ECGC
Classification |
|
Insignificant |
A1 |
|
Low |
A2 |
|
Moderate |
B1 |
|
High |
B2 |
|
Very High |
C1 |
|
Restricted |
C2 |
|
Off-credit |
D |
ALGERIA - ECONOMIC
OVERVIEW
Algeria's economy remains dominated
by the state, a legacy of the country's socialist postindependence development
model. In recent years the Algerian Government has halted the privatization of
state-owned industries and imposed restrictions on imports and foreign
involvement in its economy. Hydrocarbons have long been the backbone of the
economy, accounting for roughly 60% of budget revenues, 30% of GDP, and over
95% of export earnings. Algeria has the 10th-largest reserves of natural gas in
the world and is the sixth-largest gas exporter. It ranks 16th in oil reserves.
Strong revenues from hydrocarbon exports have brought Algeria relative
macroeconomic stability, with foreign currency reserves approaching $200
billion and a large budget stabilization fund available for tapping. In addition,
Algeria's external debt is extremely low at about 2% of GDP. However, Algeria
has struggled to develop non-hydrocarbon industries because of heavy regulation
and an emphasis on state-driven growth. The government's efforts have done
little to reduce high youth unemployment rates or to address housing shortages.
A wave of economic protests in February and March 2011 prompted the Algerian
Government to offer more than $23 billion in public grants and retroactive
salary and benefit increases, moves which continue to weigh on public finances.
Long-term economic challenges include diversifying the economy away from its
reliance on hydrocarbon exports, bolstering the private sector, attracting
foreign investment, and providing adequate jobs for younger Algerians
|
Source
: CIA |
|
SUBJECT'S NAME |
|
|
Registered Name: |
BIOCARE SARL |
|
Requested Name: |
SARL BIOCARE |
|
Other Names: |
None |
|
Physical Address: |
RN 44 Sidi Kassi Ben Mhidi El Tarf 36242 |
|
Country: |
Algeria |
|
Phone: |
213-38690132/28 |
|
Cell: |
213-550983183/560036599 |
|
Fax: |
213-38690129/30 |
|
Email: |
contact@biocare-dz.com/r.benamara@biocare-dz.com/dsi@groupe-biocaire.com |
|
Website: |
www. biocare-dz.com |
|
Financial
Index as of December 2014 shows subject firm with a medium risk of credit.
However, bank and credit information obtained reveal a history of prompt
payments. We recommend Credit of USD 300,000 on 90 days. |
|
Legal Form: |
Societe Anonyme Responsabilitee Limitee |
|
|
Date Incorporated: |
01-Jan-1998 |
|
|
Started: |
2003 |
|
|
Reg. Number: |
98B0362106 |
|
|
Tax
Number: |
099836039001128 |
|
|
VAT
Number|: |
36030499911 |
|
|
Nominal Capital |
DZD. 1,300,000,000 |
|
|
Subscribed Capital |
DZD. 1,300,000,000 |
|
|
Subscribed Capital is Subscribed in the following form: |
||
|
|
Position |
Shares |
|
Mr. Mohamed Reda Habbes |
Chairman |
|
|
Mr. Rafik Benamara |
MD |
|
|
Mrs. Samira Boulsina Habbes |
Director |
|
|
Mr. Mohamed Ali Fethi |
Director |
|
|
None |
Parent company. |
|
BIOCARE LABORATORIES |
Subsidiary company. |
|
None |
Affiliated company. |
|
None |
Shareholder of subject firm. |
|
Centre Des Affaires Et De Commerce El Qods Bureau 9/16 Bloc E Niveau 05 Cheraga Rp |
Branches of the firm |
|
Registered to operate manufacture and supply of pharmaceuticals |
|
|
Imports: |
Asia, Europe |
|
Exports: |
Africa |
|
Trademarks: |
None |
|
Terms of sale: |
Cash (40%) and 25-90 days (60%), invoices. |
|
|
|
|
Main Customers: |
Distributors, medical firms and organizations |
|
Employees: |
457 employees. |
|
Vehicles: |
Several motor vehicles. |
|
Territory of sales: |
Algeria |
|
Location: |
Owned premises, 100,000 square feet, |
|
Auditors: |
Information not available. |
|
Insurance Brokers: |
Information not available. |
|
Currency Reported: |
Algerian Dinar (DZD.) |
|
|
Approx. Ex. Rate: |
1 US Dollar = 87.94 Algerian Dinar |
|
|
Fiscal Year End: |
December 31, 2014 |
|
|
Inflation: |
According to information given by independent sources, the inflation at December 31st, 2014 was of 13%. |
|
|
|
||
|
Financial Information not Submitted |
|
|
|
|
|
|
|
|
|
|
|
Profit and Loss (expressed in DZD.) |
||
|
|
|
2014 |
|
Sales |
|
15,000,000,000 |
|
Bank Name: |
Banque de Développement Local (BDL). |
|
Branch: |
Algeria |
|
Comments: |
None |
|
Experiences: |
Good |
None
|
This
information was obtained from outside sources other than the subject company
itself and confirmed the above subject. |
FOREIGN EXCHANGE RATES
|
Currency |
Unit
|
Indian Rupees |
|
US Dollar |
1 |
Rs.62.16 |
|
|
1 |
Rs.94.28 |
|
Euro |
1 |
Rs.73.73 |
INFORMATION DETAILS
|
Analysis Done by
: |
SUB |
|
|
|
|
Report Prepared
by : |
NIS |
RATING EXPLANATIONS
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
|
>86 |
Aaa |
Possesses an extremely sound financial base with the strongest
capability for timely payment of interest and principal sums |
Unlimited |
|
|
71-85 |
Aa |
Possesses adequate working capital. No caution needed for credit transaction.
It has above average (strong) capability for payment of interest and
principal sums |
Large |
|
|
56-70 |
A |
Financial & operational base are regarded healthy. General unfavourable
factors will not cause fatal effect. Satisfactory capability for payment of
interest and principal sums |
Fairly Large |
|
|
41-55 |
Ba |
Overall
operation is considered normal. Capable to meet normal commitments. |
Satisfactory |
|
|
26-40 |
B |
Capability to overcome financial difficulties seems comparatively
below average. |
Small |
|
|
11-25 |
Ca |
Adverse factors are apparent. Repayment of interest and principal sums
in default or expected to be in default upon maturity |
Limited with
full security |
|
|
<10 |
C |
Absolute credit risk exists. Caution needed to be exercised |
Credit not
recommended |
|
|
-- |
NB |
New Business |
-- |
|
This score serves as a reference to assess
SC’s credit risk and to set the amount of credit to be extended. It is
calculated from a composite of weighted scores obtained from each of the major
sections of this report. The assessed factors and their relative weights (as
indicated through %) are as follows:
Financial
condition (40%) Ownership
background (20%) Payment
record (10%)
Credit history
(10%) Market trend (10%) Operational size
(10%)
This report is issued at your request without any
risk and responsibility on the part of MIRA INFORM PRIVATE LIMITED (MIPL) or
its officials.